DelveInsight’s “Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Post Bariatric Hypoglycemia, historical and forecasted epidemiology, as well as the Post Bariatric Hypoglycemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

The Post Bariatric Hypoglycemia Market is an evolving segment of the global healthcare landscape, driven by the increasing prevalence of the disorder and the continuous development of innovative treatment options. The Post Bariatric Hypoglycemia market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

 

Discover Key Insights into the Post Bariatric Hypoglycemia Market with DelveInsight’s In-Depth Report @ Post Bariatric Hypoglycemia Market Size

 

Key Takeaways from the Post Bariatric Hypoglycemia Market Report

• In October 2024:- Recordati Group- A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia. All participants completing the core phase will be offered to enter the extension phase. Participants will openly self-administer pasireotide 50 µg or pasireotide 100 µg or pasireotide 200 µg subcutaneously three times a day for a total of 36 weeks of treatment. There will be no more placebo during this extension phase of treatment.
• In 2023, the total postbariatric hypoglycemia cases in the 7MM were estimated to be approximately 110,000 cases which, as per DelveInsight’s estimates, will increase by 2034.
• In 2023, the US accounted for the highest cases of postbariatric hypoglycemia with approximately 80% cases.
• As per DelveInsight’s analysis, in 2023, there were higher cases of postbariatric hypoglycemia in sleeve gastrectomy cases, which was followed by Roux-en-Y gastric bypass cases, and cases in others in the US.
• As per severity of postbariatric hypoglycemia, there were more than 90% cases in the mild to moderate category in 2023, in the United States.
• There were nearly 50,000 treated cases of postbariatric hypoglycemia in 2023 in the United States.
• The leading Post-Bariatric Hypoglycemia companies such as XOMA, Zealand Pharma A/S, Eiger BioPharmaceuticals, Xeris Pharmaceuticals, Inc, Bayer, Emcure Pharmaceuticals, Virtus, Mylan N.V., Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Exela Pharma Sciences, LLC, Novartis AG, WOCKHARDT, Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Micro Labs Ltd, and others.
• Promising Post-Bariatric Hypoglycemia Therapies such as Pasireotide Diaspartate, glucagon, Lyo avexitide, Dasiglucagon, and others.

 

Stay ahead in the Post Bariatric Hypoglycemia Therapeutics Market with DelveInsight’s Strategic Report @ Post Bariatric Hypoglycemia Market Outlook

 

Post Bariatric Hypoglycemia Epidemiology Segmentation in the 7MM

• Post Bariatric Hypoglycemia Type-specific Bariatric Surgery Cases
• Postbariatric Hypoglycemia Cases in types of Bariatric Surgeries
• Severity-specific Postbariatric Hypoglycemia Cases
• Total Post Bariatric Hypoglycemia Treated cases

 

Download the report to understand which factors are driving Post Bariatric Hypoglycemia epidemiology trends @ Post Bariatric Hypoglycemia Prevalence

 

Postbariatric Hypoglycemia Emerging Drugs Profile

• Mizagliflozin: Vogenx

Mizagliflozin follows an oral route of administration and minimally absorb the inhibitor of Sodium-glucose transporter 1 (SGLT1). Postbariatric Hypoglycemia patients have elevated SGLT1 levels in the gut. This elevated blood glucose stimulates uncontrolled insulin secretion in postbariatric hypoglycemia patients. In February 2024, Vogenx announced completion of patient enrollment of a mid-Phase II clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients diagnosed with post-bariatric hypoglycemia.

• AVEXITIDE (exendin 9-39): Eiger BioPharmaceuticals

AVEXITIDE (exendin 9-39) is a 31-amino acid peptide that selectively targets and blocks GLP-1 receptors, reducing dysregulated insulin secretion by the pancreas and reducing fasting and postprandial hypoglycemia. In June 2023, the company announced that the US FDA has granted breakthrough therapy designation to AVEXITIDE for the treatment of postbariatric hypoglycemia.

 

Postbariatric Hypoglycemia Market Outlook

Most of the therapies are based on case series or reports and extrapolated from their use in other conditions that cause hypoglycemia. Acarbose has been used as first-line treatment, although adverse gastrointestinal symptoms limit this option. Diazoxide and octreotide have been used with mixed results, but side effects and patient nonadherence limit their utility. Interestingly, exogenous GLP-1 receptor agonists have also demonstrated improvement in PBH, possibly through down regulation of insulin secretion from β-cells and increased secretion of glucagon from α-cells during conditions of hypoglycemia.

 

Get In-Depth Knowledge on Post Bariatric Hypoglycemia Market Trends and Forecasts with DelveInsight @ Post Bariatric Hypoglycemia Treatment Market

 

Scope of the Post Bariatric Hypoglycemia Market Report

• Coverage- 7MM
• Post-Bariatric Hypoglycemia Companies- XOMA, Zealand Pharma A/S, Eiger BioPharmaceuticals, Xeris Pharmaceuticals, Inc, Bayer, Emcure Pharmaceuticals, Virtus, Mylan N.V., Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Pfizer Inc, Exela Pharma Sciences, LLC, Novartis AG, WOCKHARDT, Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Micro Labs Ltd, and others.
• Post-Bariatric Hypoglycemia Therapies- Pasireotide Diaspartate, glucagon, Lyo avexitide, Dasiglucagon, and others.
• Post Bariatric Hypoglycemia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Post Bariatric Hypoglycemia Unmet Needs, KOL’s views, Analyst’s views, Post Bariatric Hypoglycemia Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Post Bariatric Hypoglycemia Market Report @ Post Bariatric Hypoglycemia Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. Postbariatric Hypoglycemia (PBH) Market Overview at a Glance

4. Executive Summary of Postbariatric Hypoglycemia

5. Disease Background and Overview

6. Methodology

7. Epidemiology and Patient Population

8. Patient Journey

9. Emerging Therapies

10. Postbariatric Hypoglycemia (PBH): Seven Major Market Analysis

11. KOL Views

12. SWOT Analysis

13. Unmet Needs

14. Market Access and Reimbursement

15. Appendix

16. DelveInsight Capabilities

17. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/